Drugmaker Asks FDA To Rescind Rare Disease Status, Perks For COVID-19 Drug
By renouncing the special status, Gilead Sciences lets go of tax breaks, fee waivers and 7 years without generic competition for remdesivir, its experimental coronavirus treatment.
In a surprising turnabout, drugmaker Gilead Sciences asked the Food and Drug administration on Wednesday to rescind orphan status for remdesivir, the company's experimental coronavirus treatment.
The agency , prompting a backlash from public health and consumer
